PEBP1 and colorectal carcinoma: Recent reports indicate that RKIP may serve as a potential biomarker in Dukes’ B CRC patients and used to identify ‘high-risk’ patients with aggressive CRC and these patients should be considered for adjuvant therapy, which may be dependent on intratumoural heterogeneity[46,47].